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The physiologic control of cytokine receptor activa-
tion is primarily mediated by reciprocal activation of
receptor-associated protein tyrosine kinases and
protein tyrosine phosphatases (PTPs). Here, we
show that immediately after ligand-dependent activa-
tion, interleukin (IL)-4 receptor generated reactive ox-
ygenspecies (ROS) viaphosphatidylinositol 3-kinase-
dependent activation of NAD(P)H oxidase (NOX)1 and
NOX5L. ROS, in turn, promoted IL-4 receptor activa-
tion by oxidatively inactivating PTP1B that physically
associated with and deactivated IL-4 receptor. How-
ever, ROS were not required for the initiation of IL-4
receptor activation. ROS generated by other cytokine
receptors, including those for erythropoietin, tumor
necrosis factor-a, or IL-3, also promoted IL-4 signal-
ing. These data indicate that inactivation of recep-
tor-associated PTP activity by cytokine-generated
ROS is a physiologic mechanism for the amplification
of cytokine receptor activation in both cis and trans,
revealing a role for ROS in cytokine crosstalk.
INTRODUCTION
Interleukin (IL)-4 is an immunomodulatory type I cytokine se-
creted by activated Th2 lymphocytes, basophils, and mast cells
(Haque and Sharma, 2006; Nelms et al., 1999). It executes pleio-
tropic functions, including induction of Th2 differentiation, immu-
noglobulin class switching and B cell proliferation, and suppres-
sion of Th1 differentiation and macrophage activation, among
others (Nelms et al., 1999). IL-4, like many other cytokines, initi-
ates transmembrane signaling by tyrosine phosphorylation of
cognate receptors. Protein tyrosine phosphorylation is a tightly
regulated, reversible process in which the forward reaction is
catalyzed by receptor-associated janus kinases (JAKs) and the
reverse reaction by protein tyrosine phosphatases (PTPs) (Ha-
que and Sharma, 2006; Heldin, 1995). In the absence of cytokine
engagement, the receptor-associated PTP dominates over the
JAK, thereby holding the receptor in an inactive state (Fischer
et al., 1991; Haque and Sharma, 2006). Binding of cytokine in-
duces aggregation of receptor chains, leading to the trans-phos-phorylation of JAKs on signature tyrosine residues. This in-
creases JAKs’ catalytic activities that promote the forward
reaction, thereby stabilizing the receptor activation (Haque and
Sharma, 2006; O’Shea et al., 2002).
This is an established mechanism for receptor activation by
a majority of cytokines, including IL-4 (Haque and Sharma,
2006). However, in principle, inactivation of receptor-associated
PTP(s) could be an alternate means of receptor activation. As
a proof of the principle, we have previously demonstrated that
blockade of IL-4 receptor-associated PTP activity by pervana-
date (PV) induces receptor activation in the absence of IL-4 bind-
ing (Haque et al., 1997). However, PV is a nonphysiologic agent
that irreversibly inactivates PTPs. Recent studies have shown
that catalytic cysteines of PTPs are reversibly oxidized and inac-
tivated by reactive oxygen species (ROS), including superoxide
and hydrogen peroxide (Rhee et al., 2000). ROS are produced
by the NAD(P)H oxidase (NOX)/dual oxidase (DUOX) family
enzymes in response to cytokine or growth-factor stimulation
of cells (Rhee et al., 2000). The NOX/DUOX family is comprised
of seven members, NOX1 through NOX5, DUOX1, and DUOX2,
each exhibiting cell-type-specific expression (Lambeth, 2004;
Lambeth et al., 2007). The catalytic subunits of NOX1, NOX2,
NOX3, and NOX4 each form a membrane-integrated heterodi-
meric complex with the p22phox subunit, which is required
for their enzymatic activities (Lambeth et al., 2007). NOX2, the
founding member of the NOX/DUOX family, requires the regula-
tory subunits p47phox, p67phox, p40phox, and Ras-related C3
botulinum toxin substrate (RAC)1/RAC2, whereas NOX1 is regu-
lated by NOX organizer (NOXO)1, NOX activator (NOXA)1, and
RAC1 (Lambeth et al., 2007). NOX3- and NOX4-specific regula-
tory subunits are not known. The long isoforms of NOX5
(NOX5L), DUOX1, and DUOX2 require calcium for their functions
(Banfi et al., 2001; Lambeth, 2004; Lambeth et al., 2007).
IL-4 activates two types of receptors. The type I receptor is
comprised of the JAK1-bound IL-4Ra and JAK3-bound common
gamma chain (gc). Many nonhematopoietic cells that do not
express gc and JAK3 utilize the type II receptor in which IL-4Ra
associates with JAK2-bound IL-13Ra1 or tyrosine kinase
(TYK)2-bound IL-13Ra1 (Nelms et al., 1999). Binding of IL-4 to
IL-4Ra induces JAK1-mediated phosphorylation of multiple tyro-
sine residues in the cytoplasmic region of IL-4Ra. This, in turn,
activates two major downstream pathways, insulin-receptor
substrate (IRS)-phosphatidylinositol 3-kinase (PI3K) and signal
transducer and activator of transcription (STAT)6 (Haque andImmunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc. 551
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Reactive Oxygen Species Promote IL-4 SignalingFigure 1. IL-4 Generates ROS that Promote STAT6 Activation and Gene Expression
(A) IL-4 generates ROS in A549 cells. Cells were loaded with 5 mM CM-H2DCFDA and stimulated with IL-4 (20 ng/ml) under a fluorescence microscope before
photography.
(B) ROS generation is rapid in the early phases of IL-4 action. CM-H2DCFDA-loaded A549 cells were stimulated with IL-4 (20 ng/ml), and fluorescence intensities
were quantified. Values in relative fluorescence units (RFU) represent mean ± SE (n = 3).
(C) IL-4 generates ROS by NOX activation. A549 cells were pretreated for 2 hr with apocynin (500 mM), DPI (10 mM), L-NAME (50 mM), or DMSO, and ROS were
measured after IL-4 stimulation. RFU represent mean ± SE (n = 3; ‘‘*’’ indicates p < 0.05).
(D) Blockade of ROS generation inhibits IL-4-dependent STAT6 activation. A549 cells were pretreated with apocynin, DPI, or DMSO as described above and treated
with IL-4 (20 ng/ml) for indicated lengths of time. Cell extracts were subjected to EMSA, and relative signal intensities (RSI) were quantified with ImageQuant software.552 Immunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc.
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Reactive Oxygen Species Promote IL-4 SignalingSharma, 2006; Nelms et al., 1999). Because signal transduction,
in general, is limited in magnitude and duration, these pathways
must be uncoupled by dephosphorylation of the activated
receptor.
Here, we demonstrate that activated IL-4 receptor generated
ROS by IRS-PI3K-mediated, calcium-dependent and -indepen-
dent activation of NOX5L and NOX1, respectively. We also show
that IL-4 increased intracellular calcium flux, which is required
for NOX5L activation. ROS promoted IL-4 receptor activation
and subsequent signal transduction by oxidative inactivation of
PTP1B, a ubiquitously expressed PTP that deactivated the IL-4
receptor. Further, we provide evidence that ROS generated by
other cytokines, like IL-3, erythropoietin (EPO), and tumor necro-
sis factor (TNF)-a, markedly promoted IL-4 receptor signaling in
the same cell, revealing a role for ROS in cytokine crosstalk.
RESULTS
IL-4 Induces ROSGeneration, which Promotes Receptor
Activation and Signal Transduction
We have previously demonstrated that IL-4 receptor-associated
PTP activity is susceptible to inactivation by PV, which is an ex-
ogenous oxidant (Haque et al., 1997). Here, we demonstrate that
IL-4 stimulation of A549 cells generated endogenous oxidants,
ROS, within 10 s (Figures 1A and 1B); ROS reached a peak
at 15 min and declined thereafter (Figure S1 available online).
Although the fluorescence probe 5-(and-6)-chloromethyl-20,70-
dichloro-dihydrofluorescein diacetate (CM-H2DCFDA) used for
ROS measurement can also detect reactive nitrogen species
(RNS), pretreatment of cells with an inhibitor of nitric oxide syn-
thase, L-NAME (Kubes et al., 1991), did not reduce IL-4-gener-
ated fluorescence intensity, indicating that in response to IL-4,
A549 cells did not generate RNS (Figure 1C). To examine
whether NOX-family members were involved in IL-4-induced
ROS generation, we measured ROS in A549 cells pretreated
with diphenylene iodonuim (DPI), an inhibitor of flavoprotein
(Cross and Jones, 1986), and apocynin, which inhibits NOX
activity (Fu et al., 2006). Both inhibitors completely blocked
IL-4-induced ROS generation (Figure 1C), suggesting that
NOX-family enzymes were involved in this process. Importantly,
these inhibitors substantially reduced IL-4-dependent STAT6
activation as measured by electrophoretic mobility shift assay
(EMSA) (Figure 1D) and subsequent gene expression as as-
sessed by STAT6-responsive promoter-driven luciferase activity
(Figure 1E) (Haque et al., 2000). Similar observations were made
in mouse primary splenocytes (Figures 1F and 1G) and in other
cells of both human and mouse origins (data not shown). The
specificity of DNA-protein complexes in EMSA was confirmed
by competition with an excess of unlabeled DNA probe and by
super shift of DNA-protein complex with STAT6-specific anti-
body (Figure S2). Collectively, these data suggest that IL-4 in-duces ROS generation in all cell types examined and that ROS
induce amplification, but not initiation, of IL-4 signaling.
IL-4 Activates NOX-Family Enzymes through
the IRS-PI3K Pathway
To identify the biochemical pathways through which IL-4 in-
duces ROS generation, we used A549 as a model cell line. Bind-
ing of IL-4 to its receptor activates IRS-PI3K, STAT6, and rat sar-
coma viral oncogene homolog (RAS)-mitogen activated protein
kinase (MAPK) (in some cells) pathways (Haque and Sharma,
2006; Nelms et al., 1999). Pretreatment of cells with the JAK in-
hibitor AG490 (Meydan et al., 1996) or PI3K inhibitors LY294002
and wortmannin (Fukuchi et al., 2000), but not MAPK/extracellu-
lar signal-regulated kinase (ERK) kinase (MEK)1 inhibitor U0126
(DeSilva et al., 1998), completely blocked ROS generation by
IL-4, suggesting that JAK and PI3K activities are required for
IL-4-induced ROS generation (Figure 2A). AG490, LY294002,
and wortmannin, but not U0126, also inhibited IL-4-dependent
STAT6 activation in A549 cells (Figure 2B), further suggesting
that ROS promote IL-4-dependent signal transduction.
To confirm the role of PI3K and determine whether STAT6 has
a role in IL-4-induced ROS generation, we undertook the follow-
ing approach. IL-4 signals A549 cells through the type II receptor
(Haque and Sharma, 2006; Nelms et al., 1999). Because the
binding of IL-4 to its primary receptor, IL-4Ra, is species specific
(Ohara and Paul, 1987), A549 (human) cells did not respond to
murine IL-4 (data not shown). IL-13Ra1, which serves as a sec-
ondary receptor chain in type II IL-4 receptor complex in A549
cells, does not exhibit species specificity (Nelms et al., 1999).
We isolated cDNA of murine IL-4Ra, confirmed its functionality
(Figure S3), and generated a mutant receptor (Y500F) deficient
in activating the IRS-PI3K pathway (Nelms et al., 1999). When
expressed in A549 cells, the wild-type murine IL-4Ra efficiently
supported murine IL-4-induced ROS generation, whereas the
mutant IL-4Ra (Y500F) failed to do so (Figure 2C), confirming
that IRS-PI3K couples the IL-4 receptor to the ROS-generating
complex. In addition, inhibition of phosphatase and tensin
homolog (PTEN) expression by shRNA (Figure 2D, upper panel)
enhanced IL-4-induced ROS generation (Figure 2E) and STAT6
activation (Figure 2D, lower panel) in A549 cells. Further, overex-
pression of wild-type, but not a catalytically inactive mutant
PTEN (C124S) (Myers et al., 1997), inhibited IL-4-induced ROS
generation in A549 cells (Figure S4). Taken together, these
results confirm the requirement of PI3K activity in IL-4-induced
ROS generation.
Murine IL-4Ra did not support the activation of human STAT6
in 293T cells (Figure S3), suggesting that IL-4Ra-STAT6 interac-
tion is also species specific. Consistent with this idea, in
response to murine IL-4 treatment, A549 cells expressing the
murine IL-4Ra did not activate the endogenous (human) STAT6
(data not shown), but they efficiently supported ROS generation(E) Blockade of ROS generation inhibits IL-4-dependent gene expression. A549 cells were transfected with 4.0 mg DNA of STAT6-responsive luciferase construct.
After 48 hr, cells were pretreated with 500 mM apocynin (or DMSO) for 2 hr and stimulated with IL-4 (20 ng/ml) for indicated lengths of time, and luciferase activity was
measured. Luciferase activities in arbitrary units (AU) are plotted as mean ± SE (n = 3; ‘‘**’’ indicates p < 0.01; ‘‘NS’’ = not significant).
(F) IL-4 generates ROS by NOX activation in mouse primary splenocytes. Splenocytes were pretreated for 2 hr with apocynin (500 mM) or DMSO, and ROS were
measured after IL-4 stimulation. RFU represent mean ± SE, (n = 3; ‘‘**’’ indicates p < 0.01).
(G) Blockade of NOX activity inhibits IL-4-dependent STAT6 activation in mouse primary splenocytes. Cells were pretreated with apocynin (500 mM) for 2 hr and
treated with IL-4 (20 ng/ml) for indicated lengths of time. Cell extracts were subjected to EMSA, and RSI were quantified.Immunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc. 553
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Reactive Oxygen Species Promote IL-4 SignalingFigure 2. PI3K Activation Is Required for
IL-4-Induced ROS Generation
(A) IL-4-induced ROS generation requires JAK and
PI3K activities. A549 cells were pretreated with
AG490 (50 mM for 6 hr), LY294002 (20 mM for
2 hr), wortmannin (10 nM for 2 hr), U0126 (25 mM
for 2 hr), or DMSO, and IL-4-induced ROS gener-
ation was measured. RFU are plotted as mean ±
SE (n = 3).
(B) Blockade of JAK or PI3K activity inhibits IL-4-
induced STAT6 activation. A549 cells were pre-
treated with the inhibitors described above and
stimulated with IL-4 (20 ng/ml) for 5 min. Cell
extracts were subjected to EMSA, and RSI were
quantified.
(C) PI3K activation is indispensable for IL-4-
induced ROS generation. A549 cells were trans-
fected with 1.0 mg of murine wild-type IL-4Ra, mu-
rine mutant IL-4Ra (Y500F), or empty vector. After
48 hr, IL-4-generated ROS were measured, and
RFU were plotted as mean ± SE (n = 3; ‘‘**’’ indi-
cates p < 0.01).
(D) Inhibition of PTEN expression increases IL-4-
dependent STAT6 activation. A549 cells were
transfected with 4.0 mg of shRNA (or scramble)
construct for PTEN. After 48 hr, total RNA was iso-
lated, and steady-state levels of PTEN mRNA were
determined by RT-PCR (upper panel). Alterna-
tively, 48 hr posttransfection, cells were stimulated
with IL-4 (20 ng/ml) for 5 min. Cell extracts were
subjected to EMSA, and RSI were quantified.
(E) Inhibition of PTEN expression increases IL-4-
induced ROS generation. A549 cells were trans-
fected as described in (D). After 48 hr, IL-4 gener-
ated ROS were measured, and RFU were plotted
as mean ± SE (n = 3; ‘‘**’’ indicates p < 0.01).(Figure 2C). Moreover, cycloheximide did not alter IL-4-induced
ROS generation in A549 and other cells (data not shown). Taken
together, these data clearly indicate that IL-4Ra-mediated ROS
generation does not require either STAT6 activation or new
protein synthesis.
IL-4 Activates NOX1
The next question was which of the NOX-family members were
involved in IL-4-induced ROS generation. We found that NOX1,
NOX4, and NOX5L were predominantly expressed in A549 cells
(Figure 3A and Figure S5A). Overexpression of NOX1 and
NOX5L, but not NOX4, in A549 cells significantly increased
IL-4-induced ROS generation (Figure S5B) and also markedly
upregulated STAT6 activation (Figure S5C). Further, inhibition
of NOX1 expression by shRNA (Figure 3B) compromised IL-4-
induced ROS generation (Figure 3C) and STAT6 activation
(Figure 3D) in A549 cells. NOX1 activation requires p22phox,
NOXA1, NOXO1, and RAC1 (Cheng et al., 2006; Frey et al.,
2006; Lambeth et al., 2007). We found that IL-4-induced
ROS generation in A549 cells was significantly increased by
overexpression of p22phox (Figure S6A) and markedly compro-
mised by either overexpression of a dominant-negative mutant
p22phox (P156Q) (Kawahara et al., 2005) or shRNA-mediated in-
hibition of p22phox expression (Figure S6A). In addition, reconsti-
tution of NOX1 complex in A549 cells by overexpression of NOX1,
NOXO1, and NOXA1 significantly increased IL-4-induced ROS554 Immunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc.generation (Figure S6B). Moreover, IL-4-induced ROS generation
was inhibited by overexpression of a dominant-negative mutant
RAC1 (T17N) (Cool et al., 1998) (Figure S6C). Further, IL-4 stimu-
lation of A549 cells markedly increased RAC1 activation, which
was compromised by inhibition of PI3K activity (Figure S6D).
Collectively, these data demonstrate that IL-4 activates NOX1
complex through the IRS-PI3K-RAC1 pathway.
IL-4 Activates NOX5L
Next, we demonstrated the involvement of NOX5L in IL-4-in-
duced ROS generation and STAT6 activation by overexpression
(Figures S5B and S5C) and silencing of NOX5L gene in A549 cells
(Figures 3B–3D). Because NOX5L activation requires calcium
binding (Banfi et al., 2004; Lambeth et al., 2007), we examined
whether IL-4-induced ROS generation was dependent on in-
tracellular calcium flux. Pretreatment of A549 cells with BAPTA-
AM, a general calcium chelator (Tsien, 1980), or heparin, an
inhibitor of inositol 1,4,5-triphosphate (IP3)-receptor-mediated
calcium flux (Seuwen and Boddeke, 1995), but not nifedipine,
a blocker of L-channel-mediated calcium flux (Reid et al.,
1997), markedly inhibited IL-4-induced ROS generation (Fig-
ure 4A) and STAT6 activation (Figure 4B). Therefore, it was impor-
tant to determine whether IL-4 stimulation of cells increased
cytoplasmic calcium flux. Using Fluo-4AM (Murata et al., 2004),
we detected an increase in cytoplasmic calcium flux by confocal
microscopy within 5 s of IL-4 stimulation of A549 cells; it
Immunity
Reactive Oxygen Species Promote IL-4 SignalingFigure 3. NOX1 and NOX5L Are Involved in
IL-4-Induced ROS Generation
(A) Different NOX genes are expressed in A549
cells. Total RNA from cells was used for RT-PCR
with NOX-specific primers (upper panel) or for
b-actin (lower panel). The expected sizes (bp) of
PCR products are indicated below, and nonspe-
cific products are indicated by asterisks.
(B) Inhibition of NOX1 and NOX5L expression by
shRNA. A549 cells were transfected with 4.0 mg
of shRNA constructs for NOX1, NOX5L, or their
scramble versions. After 48 hr, steady-state levels
of NOX1 and NOX5L mRNAs were determined by
RT-PCR.
(C) Inhibition of NOX1 and NOX5L expression
reduces IL-4-induced ROS generation. A549 cells
were transfected as in (B). After 48 hr, IL-4-gener-
ated ROS were measured, and RFU were plotted
as mean ± SE (n = 3; ‘‘*’’ indicates p < 0.05).
(D) Inhibition of NOX1 and NOX5L expression
reduces IL-4-dependent STAT6 activation. A549
cells were transfected as in (B). After 48 hr, cells
were stimulated with IL-4 (20 ng/ml) for 5 min.
Cell extracts were subjected to EMSA, and RSI
were quantified.continued to increase for180 s and reached a plateau thereafter
(Figures 4C and 4D). The kinetics of this calcium flux correlated
with those of IL-4-induced ROS generation (Figure 1B).
To examine the role of phospholipase C (PLC)g, which cata-
lyzes the production of IP3 and diacylglycerol (DAG) in IL-4-
induced NOX5L activation, we pretreated A549 cells with
PLCg inhibitor U73122 (Stam et al., 1998) or inhibitors of DAG-
dependent protein kinase C (PKC), calphostin C (Jarvis et al.,
1994) and Go6976 (Gschwendt et al., 1996), and found that
IL-4-induced ROS generation was significantly inhibited (Fig-
ure S7). Further, shRNA-mediated inhibition of PLCg1 and
PLCg2 expression (Figure 4E, upper panel) reduced IL-4-
induced ROS generation (Figure 4F) and STAT6 activation
(Figure 4E, lower panel) in A549 cells. Collectively, these results
demonstrate that activated IL-4 receptor induces an intracellular
calcium flux via the IRS-PI3K-PLCg pathway that probably in-
duced DAG- and calcium-dependent PKC-mediated activation
of NOX5L to generate ROS in A549 cells.
The mouse genome does not possess a gene encoding NOX5,
but it does possess genes that encode DUOX1 and DUOX2
(Lambeth, 2004; Lambeth et al., 2007). We found that mouse
CD4+ naive T cells, but not mouse embryonic fibroblasts
(MEFs), expressed DUOX1 (Figure S8A) that requires calcium
for activation (Lambeth, 2004). However, BAPTA-AM and hepa-
rin failed to inhibit IL-4-induced ROS generation in mouse T cells
(Figure S8B) and in MEFs (as expected) (Figure S8C). Because
NOX1 was predominantly expressed in both these cell types,
IL-4-induced ROS generation was probably mediated by NOX1
in these cells.
PTP1B Negatively Regulates IL-4 Signaling
To understand the biochemical basis of ROS-mediated amplifi-
cation of IL-4 signaling, we wished to examine whether ROS
generated by activated IL-4 receptor oxidatively inactivate the
IL-4 receptor-associated PTP activity. Prior to addressing this
question, it was necessary to know the molecular identity ofthe PTP that deactivates IL-4 receptor. Previously, we and others
have identified SHP-1 and CD45 that are exclusively expressed
in hematopoietic cells as negative regulators of IL-4 signaling
(Haque et al., 1998; Yamada et al., 2002). Because IL-4 induced
ROS generation in all cell types examined, we sought to identify
a ubiquitously expressed PTP that deactivates IL-4 receptor.
Screening of a panel of such PTPs by overexpression in 293T
cells identified PTP1B as a potential candidate that substantially
inhibited IL-4-dependent STAT6 activation (Figure S9A). Consis-
tently, overexpression of wild-type, but not catalytically inactive
mutant PTP1B (C215S), markedly inhibited IL-4-dependent
STAT6 activation (Figure S9B) and subsequent gene expression
in 293T cells (Figure S9C). These observations were confirmed in
immortalized embryonic fibroblasts derived from Ptpn1/ mice
(Buckley et al., 2002; Elchebly et al., 1999), which exhibited sub-
stantial increases in magnitude and duration of IL-4-induced
activation of STAT6 (Figure 5A). Further, IL-4-dependent STAT6
activation was markedly inhibited after insertion of PTP1B in
PTP1B-deficient MEFs (Figure 5B). Moreover, IL-13 that utilizes
the type II IL-4 receptor for cell signaling (Nelms et al., 1999) also
substantially increased STAT6 activation in Ptpn1/ MEFs
compared with wild-type MEFs (Figure S9D).
PTPs may exhibit functional redundancy in the regulation of
cytokine signaling pathways. SHP-1 and CD45 inhibit IL-4
signaling in hematopoietic cells (Haque et al., 1998; Yamada
et al., 2002); therefore, it was important to know whether
PTP1B negatively regulates IL-4 signaling in hematopoietic cells.
As shown in Figure 5C, IL-4-dependent STAT6 activation was
markedly increased in primary splenocytes derived from
Ptpn1/ mice. Importantly, PTP1B deficiency also increased
IL-4-induced ROS generation in both MEFs (Figure 5D) and sple-
nocytes (Figure 5E). Further, insertion of PTP1B in PTP1B-defi-
cient MEFs significantly reduced IL-4-induced ROS generation
(Figure 5D). PTP1B deficiency also increased ROS generation
by IL-4 in mouse primary macrophages, mast cells, and T cells
and by IL-13 in MEFs, splenocytes, and macrophagesImmunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc. 555
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Reactive Oxygen Species Promote IL-4 SignalingFigure 4. IL-4 Induces Calcium Flux that Increases ROS Generation
(A) IL-4-induced ROS generation is inhibited by blocking IP3-receptor-mediated calcium release. A549 cells were treated for 2 hr with BAPTA-AM (30 mM),
heparin (1 mM), nifedipine (0.1 nM), or DMSO, and IL-4-generated ROS measured in RFU are plotted as mean ± SE (n = 3; ‘‘**’’ indicates p < 0.01).
(B) Inhibition of IP3-receptor-mediated calcium release compromises IL-4-dependent STAT6 activation. A549 cells were pretreated as in (A) and treated with IL-4
(20 ng/ml) for 5 min. Cell extracts were subjected to EMSA, and RSI were quantified.
(C) IL-4-stimulation increases cytoplasmic calcium flux. A549 cells were loaded with 1 mM Fluo4-AM, and changes in cytoplasmic calcium levels were measured
with live-cell confocal microscopy. The arrow indicates the time when the medium was replaced by fresh medium containing 20 ng/ml of IL-4 or 1 mM of ionomycin
(as positive control). The experiment was performed five times, and data of one representative experiment are shown.
(D) IL-4-stimulation increases cytoplasmic calcium flux. A549 cells were processed as in (C), and confocal microscopic pictures were taken. The experiment was
performed five times, and data of one representative experiment are shown.
(E) Inhibition of PLCg1 or PLCg2 expression by shRNA reduces IL-4-dependent STAT6 activation. A549 cells were transfected with 4.0 mg of shRNA or scramble
construct for PLCg1 or PLCg2. After 48 hr, PLCg1 and PLCg2 transcript levels were determined by RT-PCR (upper panel). Alternatively, 48 hr posttransfection,
cells were stimulated with IL-4 for 5 min. Cell extracts were subjected to EMSA, and RSI were quantified.
(F) Inhibition of PLCg1 or PLCg2 expression by shRNA reduces IL-4-induced ROS generation. A549 cells were transfected as in (E). After 48 hr, IL-4-generated
ROS were measured, and RFU were plotted as mean ± SE (n = 3; ‘‘*’’ indicates p < 0.05; ‘‘**’’ indicates p < 0.01).(Figure S10). Collectively, these data demonstrate that PTP1B
functions as a nonredundant negative regulator of IL-4 and IL-
13 signaling in hematopoietic and nonhematopoietic cells.
Next, we asked whether PTP1B deficiency favors the differen-
tiation of naive CD4+T cells to Th2 effector cells. Highly purified
CD44lo naive CD4+ T cells were obtained from lymph nodes of556 Immunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc.Ptpn1+/+ and Ptpn1/ mice by cell sorting and subsequently
stimulated with anti-CD3 and anti-CD28 in the presence of irra-
diated T cell-depleted splenocytes. We included cytokines and
antibodies in the culture to induce Th1 or Th2 differentiation.
As shown in Figure 5F, enhanced IL-4 producing Th2 cells
were found in PTP1B-deficient CD4+ T cells. Enhanced IL-4
Immunity
Reactive Oxygen Species Promote IL-4 SignalingFigure 5. PTP1B Negatively Regulates IL-4 Signaling
(A) PTP1B deficiency increases IL-4-dependent STAT6 activation in MEFs. PTP1B-deficient (Ptpn1/) and wild-type (Ptpn1+/+) MEFs (immortalized) were
treated with IL-4 (20 ng/ml) for the indicated lengths of time, cell extracts were subjected to EMSA and immunoblot analysis (with anti-phospho-Tyrosine641-
STAT6), and RSI were quantified. Immunoblot analyses with anti-STAT6 and anti-b-actin served as controls.
(B) Reintroduction of PTP1B to Ptpn1/ MEFs reduces IL-4-dependent STAT6 activation. Immortalized Ptpn1/ MEFs were stably transfected with either
empty vector or PTP1B, and clones were selected in the presence of hygromycin B. Selected pools were treated with IL-4 (20 ng/ml) for 30 min, and cell extracts
were subjected to immunoblot analyses and EMSA.
(C) PTP1B deficiency increases IL-4-dependent STAT6 activation in mouse primary splenocytes. Splenocytes fromPtpn1+/+ andPtpn1/mice were treated with
IL-4 (20 ng/ml) for the indicated lengths of time, cell extracts were subjected to EMSA, and RSI were quantified.
(D) PTP1B deficiency increases IL-4-induced ROS generation in immortalized MEFs. MEFs derived fromPtpn1+/+ andPtpn1/mice and representative clones of
Ptpn1/ MEFs stably transfected with PTP1B (or empty vector) were treated with IL-4 for indicated lengths of time, and ROS were measured. RFU are plotted as
mean ± SE (n = 3; ‘‘*’’ indicates p < 0.05; ‘‘**’’ indicates p < 0.01).
(E) PTP1B deficiency increases IL-4-induced ROS generation in mouse primary splenocytes. Splenocytes isolated from Ptpn1+/+ and Ptpn1/ mice were
stimulated with IL-4 for indicated lengths of time, and ROS were measured. RFU are plotted as mean ± SE (n = 3; ‘‘**’’ indicates p < 0.01).
(F) PTP1B deficiency increases the number of IL-4-producing CD4+ T cells. Naive CD4+ T cells were purified from lymph nodes ofPtpn1+/+ andPtpn1/mice and
cultured with anti-CD3 and anti-CD28 plus T cell-depleted syngenic irradiated spleen cells as a source of antigen-presenting cells, in a ratio of 1:5, for 72 hr under
conditions inducing Th1 or Th2 differentiation. Intracellular IL-4 and IFN-g expression was determined by flow cytometry after restimulation with anti-CD3 and
anti-CD28 for 6 hr.Immunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc. 557
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Th-neutral condition (data not shown). These data suggest that
PTP1B negatively controls Th2 differentiation of naive CD4+
T cells in vitro. We also noted that PTP1B-deficient CD4+
T cells produced more IFN-g when stimulated under Th1 condi-
tion. Th1 differentiation is controlled by IL-12 and IFN-g signaling
(Nelms et al., 1999). PTP1B binds to and dephosphorylates JAK2,
thereby attenuating IFN-g signaling (Myers et al., 2001). Although
PTP1B-mediated downregulation of IL-12 signaling has not been
directly demonstrated, JAK2 and TYK2, which are required for IL-
12-mediated cell signaling (Haque and Sharma, 2006), are shown
to be potential substrates for PTP1B. Therefore, it was not
unexpected that PTP1B deficiency would increase the number
of IFN-gproducing cells under Th1-skewed condition (Figure 5F).
PTP1B Deactivates IL-4 Receptor
Next, to determine whether PTP1B dephosphorylates IL-4
receptor, we used a chimeric receptor, EPOR-IL-4Ra, composed
of the extracellular and transmembrane domains of the murine
EPO receptor and the cytoplasmic domain of the human IL-4Ra
(Figure S11A). When coexpressed with STAT6 in 293T cells
(which do not express endogenous functional STAT6), this recep-
tor becomes activated upon EPO binding and induces STAT6
activation (Haque et al., 2000). PTP1B substantially inhibited
EPO-dependent tyrosine phosphorylation of EPOR-IL-4Ra and
subsequent activation of STAT6 in 293T cells (Figure 6A), sug-
gesting that PTP1B may interact with IL-4Ra, JAK1, or STAT6.
However, a previous study has shown that JAK1 does not bind
to PTP1B (Myers et al., 2001). To determine whether PTP1B binds
to IL-4Ra and/or STAT6, either wild-type PTP1B or substrate-
trapping mutant PTP1B (D181A) (Flint et al., 1997) was coex-
pressed with EPOR-IL-4Ra and/or STAT6 in 293T cells. Employ-
ing conventional coimmunoprecipitation technique, we could not
detect physical association of PTP1B with either EPOR-IL-4Raor
STAT6 (data not shown). However, when cell lysates were
prepared in the presence of the chemical crosslinking agent
dithio[succimidyl propionate] (DSP) (Maiti et al., 2005), PTP1B
was found to form a complex with IL-4Ra, but not STAT6
(Figure 6B), suggesting that the interaction between PTP1B and
IL-4Ra was weak and dynamic in nature. Further, using deletion
mutants of EPOR-IL-4Ra (Figure S11B), we mapped a PTP1B-
interacting region in IL-4Ra to a region encompassing the
STAT6-docking sites (Nelms et al., 1999) (Figure S11C).
Bioluminescence resonance energy transfer (BRET) is a pow-
erful tool for the detection of weak and dynamic protein-protein
interactions in live cells (Pfleger and Eidne, 2006). Employing this
technique, we detected an interaction between PTP1B (D181A)
and IL-4Ra, even in the absence of IL-4 stimulation; the interac-
tion was increased by IL-4 stimulation of cells (Figure 6C). These
results confirmed the in vitro crosslinking data indicating that
PTP1B physically associates with IL-4Ra.
ROS Inactivate PTP1B by Oxidation of Its Catalytic
Cysteine and Mediate Cytokine Crosstalk
ROS-mediated oxidative inactivation of PTP1B has been dem-
onstrated both in vitro (Salmeen et al., 2003; van Montfort
et al., 2003) and in vivo by insulin and epidermal growth factor
(EGF) (Lee et al., 1998; Mahadev et al., 2001; Meng et al.,
2002). Because we found that IL-4 induced ROS generation558 Immunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc.Figure 6. PTP1B Binds to and Dephosphorylates IL-4Ra
(A) PTP1B deactivates IL-4Ra. 293T cells were transfected with 50 ng of
STAT6 and 5.0 mg of chimeric EPOR-IL-4RaV5, along with 5.0 mg of
PTP1B or vector. After 48 hr, cells were treated with EPO (5 U/ml) for 5 min,
and cell extracts were subjected to EMSA. Immunoprecipitates derived from
1.0 mg proteins or 50 mg proteins (cell lysate) were used for immunoblotting.
The experiment was repeated two times, and similar results were obtained.
(B) PTP1B physically associates with the cytoplasmic domain of IL-4Ra. In
lanes 1 to 6, 293T cells were transfected with EPO-IL-4Ra-V5 (2.0 mg),
untagged STAT6 (2.0 mg), and 4.0 mg of wild-type PTP1B-FLAG, mutant
PTP1B (D181A)-FLAG, or empty vector. In lanes 7 to 12, cells were transfected
with 2.0 mg of STAT6-V5 and 4.0 mg wild-type PTP1B-FLAG, mutant PTP1B
(D181A)-FLAG, or empty vector. After 48 hr, cells were treated with EPO
(5 U/ml) or IL-4 (20 ng/ml) for 5 min. Cell lysates were prepared in the presence
of DSP and immunoprecipitated (IP) with anti-FLAG, decrosslinked, and
subjected to immunoblot analyses along with decrosslinked total lysates.
(C) PTP1B interacts with IL-4Ra in live cells. For BRET assay, 293T cells were
transfected with 1.0 mg of the donor plasmid pIL-4Ra-LUC-N3 and 3.0 mg of an
acceptor plasmid pGFP2-N2 (empty vector), STAT6-GFP2-N2, or PTP1B-
D181A-GFP2-N2 with Lipofectamine 2000 (Invitrogen). After 48 hr, cells were
used for BRET assay, and the calculated BRET ratios are plotted as mean ±
SE (n = 3).
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was important to examine whether IL-4-generated ROS could
cause oxidative inactivation of PTP1B. Using a monoclonal anti-
body against oxidized PTP-active site (Persson et al., 2004), we
observed a time-dependent oxidation of the catalytic cysteine
215 of PTP1B in A549 cells after stimulation with IL-4 (Figure 7A)
or IL-13 (Figure 7B). Further, pretreatment of these cells with
apocynin or LY294002 that completely inhibited IL-4-induced
ROS generation (Figures 1C and 2A) markedly reduced the oxida-
tion of PTP1B (Figure 7C). Moreover, shRNA-mediated reduction
of NOX1 or NOX5L expression, which significantly decreased
IL-4-induced ROS generation (Figure 3C), substantially inhibited
IL-4-induced oxidation of PTP1B in A549 cells (Figure 7D). IL-4
also induced a time-dependent oxidation of PTP1B in primary
mouse splenocytes (Figure 7E) and bone marrow-derived macro-
phages (Figure 7F). These results clearly demonstrate that ROS-
mediated amplification of IL-4 (or IL-13) signaling was, in part,
due to oxidative inactivation of PTP1B, in both primary and
immortalized cells.
Under physiologic settings, multiple cytokines may act on
a single cell that expresses the cognate receptors. Because
ROS are small and diffusible radicals or molecules, oxidative
inactivation of PTP1B by other cytokine-generated ROS may
amplify the activation of IL-4 receptor in the same cell. To exam-
ine this possibility, we expressed in A549 cells the mutant murine
IL-4Ra (Y500F) that did not generate ROS (Figure 2C) but sup-
ported STAT6 activation in response to murine IL-4 stimulation
(Figure 7G). As shown in Figure 7G, a simultaneous stimulation
of these cells with EPO and murine IL-4 substantially increased
STAT6 activation. EPO did not activate STAT6 (Figure 7G), but
it induced ROS generation in these cells (Figure S12A). These
results suggest that EPO-generated ROS can act in trans to pro-
mote IL-4 signaling in the same cell. Further, to examine whether
EPO or other cytokines can promote IL-4 signaling through
its endogenous receptor, we pretreated A549 cells with EPO or
TNF-a and then treated them with IL-4 in the presence or ab-
sence of PI3K inhibitor LY294002. Figure 7H shows that both
EPO and TNF-a markedly promoted the activation of endoge-
nous IL-4 receptors in A549 cells. Similar observations were
made in mouse primary splenocytes in which ROS generated
by IL-3 or TNF-a (Figures S12B and S12C) markedly increased
IL-4-dependent STAT6 activation (Figures 7I and 7J). Of note
is the fact that LY294002 completely blocked EPO- and TNF-
a-induced ROS generation in A549 cells but failed to completely
inhibit IL-3- and TNF-a-induced ROS generation in primary sple-
nocytes (Figure S12), suggesting that IL-3 and TNF-a may also
induce ROS generation by PI3K-independent mechanism(s). Im-
portantly, the amounts of IL-3- or TNF-a-generated ROS corre-
lated with the extents of STAT6 transactivation (Figures 7G–J).
Collectively, these results demonstrate that ROS produced by
activation of other cytokine receptors were able to promote the
activation of IL-4 receptor in the same cell, suggesting that
ROS can serve as a physiologic mediator of crosstalk between
different cytokine receptors (Figure S13).
DISCUSSION
In this study, we have demonstrated that immediately after IL-4
engagement, activated receptor produced ROS that, in turn, in-creased the magnitudes of receptor activation and consequent
signal transduction in all IL-4-responsive cells examined, in the
absence of de novo protein synthesis and STAT6 activation. Sub-
sequently, undertaking multiple complementary approaches, we
have demonstrated that IL-4 induced the activation of NOX1 and
NOX5L through PI3K-RAC1 and PI3K-PLCg, respectively.
The mechanisms of NOX1 activation are characterized in
a number of cell types. NOX1 requires p22phox, NOXA1,
RAC1, and NOXO1 for activation (Lambeth et al., 2007). Typi-
cally, NOXO1 is recruited to NOX1-p22phox complex, to which
NOXA1 is recruited by activated RAC1 (Lambeth et al., 2007).
An earlier report showed that IL-4 activates RAC1 in human ker-
atinocytes (Wery-Zennaro et al., 2000), but it is not known
whether IL-4-activated RAC1 induces NOX1 activation. Our
results demonstrate that phosphorylation of specific tyrosine
(Y497 in human and Y500 in mouse) in IL-4Ra that recruits
IRS-PI3K was required for IL-4-dependent ROS generation by
NOX1 and NOX5L (in human cells). PI3K-dependent regulation
of NOX-mediated ROS generation has previously been demon-
strated in EGF- and TNF-a-stimulated cells (Frey et al., 2006;
Park et al., 2004). We found that IL-4-activated PI3K-dependent
RAC1 activation was indispensable for ROS generation in A549
cells, suggesting that IL-4 activates RAC1 through PI3K, and
RAC1 is involved in ROS generation by NOX1, as dominant-
negative mutant RAC1 (T17N) compromised ROS generation
by IL-4.
IL-4-dependent ROS generation was also significantly re-
duced by inhibitors of cytoplasmic calcium flux, suggesting
that calcium flux was required for IL-4-induced NOX5L activa-
tion. It was not known whether IL-4 induced calcium flux. Using
Fluo-4AM, whose fluorescence intensity increases >100-fold
upon calcium binding (Harkins et al., 1993), we demonstrated
that IL-4 induced an immediate cytoplasmic calcium flux in
A549 cells. IL-4-induced ROS generation was inhibited by
shRNA or small-molecule inhibitor of PLCg1 and PLCg2. Two
studies have previously demonstrated the role for PLCg1 in
IL-4 signaling (Ikizawa et al., 1994; Ikizawa and Yanagihara,
2000), whereas another report has implicated a role of phospha-
tidylcholine-specific PLC, but not PLCg, in IL-4 signaling (Za-
morano et al., 2003). This discrepancy may be due to the latter
study’s use of mouse cells, which do not express NOX5 (Banfi
et al., 2001). Interestingly, IL-4-dependent ROS generation was
markedly reduced by the inhibition of DAG-dependent PKCs. A
recent study showed that activation of NOX5L is regulated by un-
identified PKC-mediated phosphorylation of a serine and a thre-
onine located in the FAD-binding domain of NOX5 (Jagnandan
et al., 2007). Previous studies have focused on DAG- and cal-
cium-independent PKC-mediated regulation of IL-4 signaling
(Duran et al., 2004; Ho et al., 1994). Our results suggest a role
for classical PKCs that depend on both DAG and calcium for ac-
tivation in IL-4-mediated cell signaling. The mouse genome does
not contain a gene encoding NOX5, but it does contain genes en-
coding DUOX1 and DUOX2, which require calcium for activation.
We noted that mouse T cells, but not MEFs, expressed DUOX1;
however, calcium blockers did not inhibit IL-4-induced ROS gen-
eration, suggesting that IL-4-induced ROS generation was cata-
lyzed by NOX1, which was predominantly expressed in both the
mouse cell types. Further studies are necessary to confirm
whether IL-4 induces calcium flux and whether it is required forImmunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc. 559
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(A and B) Oxidation of PTP1B in IL-4- or IL-13-stimulated A549 cells. Cells were treated with 20 ng/ml of IL-4 (A) or 10 ng/ml of IL-13 (B) for indicated lengths of
time, with 3 mM H2O2 (positive control) for 5 min, or were left untreated. Cell lysates were prepared in the presence (upper panel) or absence (lower panel) of IAA
and immunoprecipitated with anti-PTP1B, and the immune complexes were subjected to immunoblot analysis with a monoclonal antibody that recognizes ox-
idized PTP1B.
(C) Blockade of ROS generation inhibits PTP1B oxidation in IL-4-stimulated cells. A549 cells were treated with 500 mM apocynin, 20 mM LY294002, or DMSO for
2 hr prior to measurement of IL-4-induced oxidation of PTP1B. The upper and lower panels represent results derived from cell lysates prepared in the presence
and absence of IAA, respectively. The experiment was repeated two times, and similar results were obtained.
(D) Inhibition of NOX1 or NOX5L expression reduces IL-4-induced PTP1B oxidation. A549 cells were transfected with 4.0 mg of shRNA or scramble constructs for
NOX1 or NOX5L. After 48 hr, cells were treated with IL-4 (20 ng/ml) or H2O2 (3 mM) for 5 min or left untreated. Cell lysates were prepared in the presence or
absence of IAA, and PTP1B oxidation was measured.
(E and F) IL-4-generated ROS induce PTP1B oxidation in mouse primary hematopoietic cells. Splenocytes (E) and bone marrow-derived macrophages (F) were
stimulated with IL-4 for indicated lengths of time or with 3 mM H2O2 for 5 min. Cell lysates were prepared in the presence or absence of IAA, and PTP1B was
oxidation measured.
(G) EPO-generated ROS promote IL-4-dependent STAT6 activation. A549 cells were transfected with 1.0 mg of murine IL-4Ra (Y500F), along with 3.0 mg of murine
STAT6 plasmid. After 48 hr, cells were treated for 5 min with EPO (5U/ml) and murine IL-4 (20 ng/ml), either singly or in combination. Cell extracts were subjected
to EMSA, and RSI were quantified.
(H) TNF-a- and EPO-generated ROS promote endogenous IL-4 receptor activation in A549 cells. Cells pretreated with LY294002 (20 mM) or DMSO for 2 hr were
stimulated for 3 min with EPO (5U/ml) or TNF-a (10 ng/ml), followed by treatment with human IL-4 (20 ng/ml) for 2 min. Cell extracts were subjected to EMSA, and
RSI were quantified.
(I and J) TNF-a- and IL-3-generated ROS promote endogenous IL-4 receptor activation in mouse primary splenocytes. After pretreatment for 2 hr with LY294002
(20 mM) (I) or apocynin (500 mM) (J), cells were treated for 3 min with TNF-a (10 ng/ml) or IL-3 (10 ng/ml), followed by treatment with mouse IL-4 (20 ng/ml) for 2 min.
Cell extracts were subjected to EMSA, and RSI were quantified.560 Immunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc.
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cell types.
We found that IL-4-generated ROS promoted IL-4-dependent
signal transduction and gene expression. We have demon-
strated that as an underlying mechanism, PTP1B physically
interacted with IL-4Ra and deactivated it, and IL-4-generated
ROS inactivated its catalytic cysteine 215 by oxidation in both
hematopoietic and nonhematopoietic cells. Because IL-13Ra1,
the second chain of type II IL-4 receptor, constitutively associ-
ates with JAK2 or TYK2, PTP1B-mediated attenuation of type
II IL-4 receptor activation may also be attributed to PTP1B-
catalyzed deactivation of JAK2 or TYK2 (Myers et al., 2001).
Both oxidative inactivation and genetic inactivation of PTP1B
were found to upregulate IL-4 receptor activation and signal
transduction. However, the former is a reversible and physiologic
process, whereas the latter is a nonphysiologic and irreversible
depletion of PTP1B function. PTP1B inactivation by ROS occurs
locally at the site of IL-4 receptor activation and its immediate
vicinity, whereas genetic inactivation of PTP1B occurs globally,
and this unleashes PTP1B-dependent restraints on all the signal-
ing pathways that are regulated by PTP1B under normal physio-
logic conditions. As a consequence, an in vitro differentiation of
PTP1B-deficient naive Th cells can be expected to be skewed to
both Th1 and Th2 lineages, given that PTP1B functions as a neg-
ative regulator of IL-4 (the current study) and IFN-g (and probably
IL-12) signaling pathways (Myers et al., 2001).
Our data also revealed that PTP1B played a nonredundant role
in hematopoietic cells in which both SHP-1 and CD45 are found
to downregulate IL-4-dependent signal transduction (Haque
et al., 1998; Yamada et al., 2002). Therefore, it remains to be
examined whether SHP-1 and CD45 are also oxidatively inacti-
vated by IL-4-generated ROS, given that the catalytic cysteine
is conserved in all PTPs and susceptible to oxidation by ROS
(Rhee et al., 2000).
ROS are small, diffusible radicals or molecules that inactivate
PTPs, including PTP1B (Rhee et al., 2000). Using IL-4 as a model
cytokine, we have uncovered a cellular mechanism underlying
the homeostatic control of cytokine receptor activation and
signal transduction by addressing how an activated cytokine re-
ceptor induced ROS generation by activating NOX enzymes to
promote the receptor’s own activation as well as the activation
of other cytokine receptors in the same cell. ROS-mediated
cytokine signaling crosstalk may be dependent on the proximity
of the different cytokine (or growth-factor) receptors and their
susceptibility to regulation by oxidative inactivation of common
PTPs. Another level of regulation may be provided by the spec-
ificity and abundance of the antioxidant proteins utilized by
different receptors for elimination of cytokine-generated ROS,
thus allowing the regeneration of reversibly inactivated PTPs
and the restoration of normal homeostasis of cellular cytokine
signaling. An understanding of the ROS-mediated cytokine
signaling crosstalk may explain the molecular basis of side
effects of cytokine therapies in a variety of human diseases. It
has been believed that the cytokine-activated JAK-STAT path-
way operates directly from the cell surface to the nucleus via
protein-protein and DNA-protein interactions, without involving
any second messengers. This study reveals a role for ROS as
a second messenger in the amplification of IL-4-mediated signal
transduction in both cis and trans.EXPERIMENTAL PROCEDURES
Cells and Reagents
A549, 293T, and NIH 3T3 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum (FCS). Immortalized
MEFs from Ptpn1+/+ and Ptpn1/ mice were maintained in DMEM supple-
mented with 15% FCS (Buckley et al., 2002). Single-cell suspensions were
prepared from mouse spleens and cultured in Iscove’s modified Dulbecco’s
medium (IMDM) supplemented with 10% FCS. Cells obtained by flushing the
mouse femur bone marrow were cultured in complete DMEM supplemented
with 10% FCS and 20% L929-conditioned medium (as a source of M-CSF) for
differentiating them into macrophages (Haque et al., 1998). For development
of mast cells, the bone marrow-derived cells were cultured for 3–4 weeks in
RPMI-1640 medium supplemented with 10% FCS, 10 mM HEPES, 1X MEM
essential amino acids, 1 mM sodium pyruvate, 10 mM b-mercaptoethanol, and
20% WEHI-3 conditioned medium (as a source of IL-3), and cells were used
whenmore than95%of themstainedpositivewith toluidineblue(Yuanetal.,1998).
All recombinant cytokines and anti-oxy-PTP were purchased from R&D
Systems. Apocynin, DPI, AG490, LY294002, wortmannin, U0126, BAPTA-
AM, U73122, Go6976, and calphostin C were obtained from Calbiochem. Ni-
fedipine, heparin, and anti-FLAG-conjugated agarose beads were purchased
from Sigma. All antibodies used for T cell isolation, differentiation, and analy-
ses were from BD PharMingen. Anti-phospho (Tyrosine641)-STAT6 and anti-
phospho-tyrosine PY100 were purchased from Cell Signaling Technology,
and anti-V5 was from Invitrogen. Anti-STAT6, anti-b-actin, anti-FLAG, and
anti-goat HRP were obtained from Santa Cruz, and anti-PTP1B was from
BD Transduction. Anti-mouse HRP and anti-rabbit HRP were purchased
from Amersham Biosciences.
All animal experiments were conducted according to the guidelines of our
Institutional Animal Care and Use Committee.
Intracellular ROS Assays
ROS were measured fluorimetrically with CM-H2DCFDA probe (Choi et al.,
2005; Myhre et al., 2003). In brief, adherent cells were washed twice with
Hank’s balanced salt solution (HBSS), incubated with 5 mM CM-H2DCFDA in
HBSS for 10 min at 37C in 5% CO2, washed, and stimulated with indicated
cytokine at 37C under a Leica DMIRB inverted microscope (Leica Microsys-
tems) equipped with a Retiga EXi Cooled CCD Camera (Q Imaging, Burnby)
with a Ex490nm and standard fluorescein filter. Images were taken every 10 s,
and fluorescence signals were quantified with Image Pro Plus software (Media
Cybernatics). Each value in relative fluorescence units (RFU) represents
mean ± SEM of three independent measurements; each measurement repre-
sents the mean fluorescence signals of five equivalent fields (approximately
same number of cells). For measuring ROS for longer time periods (>5 min),
cells were loaded with CM-H2DCFDA, trypsinized, and resuspended in
HBSS, and changes in fluorescence signals were measured with flow cytom-
etry (FACScan, Beckton-Dickinson). ROS produced by nonadherent cells
were measured with Victor2 Wallace Mutichannel Reader (Perkin Elmer) with
Ex495nm and Em535nm filters.
Electrophoretic Mobility Shift, Super-Shift, and Luciferase Assays
EMSA was performed with 10 mg proteins of whole-cell extracts and 0.2 ng
of 32P-labeled high-affinity STAT6-specific probe (Haque et al., 2000). Cell ex-
tracts were incubated with 2 mg of normal rabbit IgG or STAT6 antibody prior to
incubation with 0.2 ng of radiolabeled olionucleotide duplex for 20 min for
super-shift assay or with 10 ng or 50 ng of unlabeled wild-type or mutant
oligonucleotide duplex for competition assay. The sequences for the sense
strand of the oligonucleotide are as follows: 50-GATCGCTCTTCTTCCCAG
GAACTCA-ATG-30 (wild-type) and 50-GATCG-CTCTTCTTCCCAGGGGCTCA
ATG-30 (mutant), with the conserved N6-GAS sequence underlined (Haque
et al., 2000) and the mutated nucleotides italicized. The DNA-protein com-
plexes were resolved on native 6% polyacrylamide gels, dried, and visualized
after incubation at 80C. Luciferase assay was performed with the Dual
Luciferase Assay Kit (Promega) according to the manufacturer’s instructions.
Cloning, Site-Directed Mutagenesis, and Plasmid Constructs
Murine IL-4Ra cDNA was isolated from a NIH 3T3 cell-derived cDNA library by
PCR and cloned in pcDNA3.1/V5-HisA (Invitrogen). For BRET assay, humanImmunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc. 561
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in pGFP2-N2 (Perkin Elmer). The constructs for p22phox (wild-type and P156Q
mutant), NOX1, NOXA1, NOXO1, NOX4, NOX5L, and p22phox shRNA (spe-
cific and scramble) are described (Kawahara et al., 2005). The wild-type
(WT) and mutant (C174S) PTEN constructs were obtained from Charis Eng,
and wild-type (WT) and mutant (T17N) RAC1 constructs were obtained from
Olga Stenina. All point mutants were generated with Quick Change XL Site-
Directed Mutagenesis Kit (Stratagene) according to the manufacturer’s
instructions.
DNA oligonucleotides encoding shRNA sequences with loop sequence
(50-TTCAAGAGA-30) were cloned into pSuper-Neo (OligoEngine) according
to the manufacturer’s instructions. The specific target sense sequences
were as follows: 50-GAATTAGGCAAAGTGGGTT-30 for NOX1, 50-AAGAGCGA
TTCTTTGCCCTAT-30 for NOX5L, 50-CGGGAAGACAAGTTCATGTACTT-30 for
PTEN, 50-GAACAACCGGCTCTTCGT-30 for PLCg1, and 50-AATCCTGACTTC
CGAGAA-30 for PLCg2. The scramble versions of the target sequences were
generated with siRNA Wizard (InVivogen) and cloned in pSuper-Neo vector
(OligoEngine). All constructs were verified by nucleotide sequencing.
Transfection and Generation of Stable Clones
A549 and 293T cells were transfected with Lipofectamine 2000 (Invitrogen)
and calcium phosphate coprecipitation, respectively (Haque et al., 2000),
with transfection efficiencies of 70%–80% and 90%, respectively. Stable
clones of immortalized PTP1B-deficient MEFs were generated by selection
with 150 mg/ml hygromycin B (Invitrogen) for 2 weeks.
Reverse Transcriptase-Polymerase Chain Reaction
For determination of mRNA levels, 1.0 mg of total RNA was used for first-strand
cDNA synthesis according to the manufacturer’s protocol (Invitrogen). One-
tenth of cDNA was used as a template for 35 cycles of PCR with specific primer
sets listed in Table S1.
RAC1 Activation Assay
A549 cells were treated with 20 mM LY294002 or DMSO (vehicle) for 2 hr, after
which the cells were treated with IL-4 (20 ng/ml) for 5 min or left untreated. Cell
lysates were used for detection of active RAC1 with the RAC1/Cdc42 Activa-
tion Assay Kit (Millipore) according to the manufacturer’s instructions.
Measurement of Cytoplasmic Calcium Flux
For measurement of cytoplasmic calcium flux, cells were incubated with the
calcium indicator dye Fluo4-AM (1 mM) for 30 min in complete DMEM accord-
ing to the manufacturer’s instructions (Molecular Probes). Before measure-
ment of fluorescence signals, cells were washed twice with phenol red-free
DMEM and incubated for another 15 min for complete hydrolysis of intracellu-
lar AM-esters. Images of cells were taken both before and after IL-4 stimula-
tion, at every 2 s for 6 min at 37C. Images were obtained with Leica SP-2
AOBS confocal microscope (Leica-Microsystems) with an HCX PL APO
403/1.25 NA oil-immersion objective lens (Murata et al., 2004), with minor
modifications. Fluo4 was excited with the 488 nm line of an argon laser, and
its fluorescence emission was recorded between 500 and 550 nm with the
built-in spectrophotomer. Illumination intensity was kept to a minimum
(50 mW) for avoidance of phototoxicity, and the pinhole was set to 2 Airy units.
Fluorescence signals were quantified with Leica confocal software (Leica-
Microsystems).
In Vitro T Cell Differentiation
Single-cell suspensions of mouse lymph node cells were incubated with FITC-
conjugated anti-CD8, anti-B220, anti-MHC class II (Fh2d), and anti-FcgR and
then incubated with anti-FITC microbeads (Miltenyi Biotec). The negative frac-
tion obtained after magnetic separation with an LS magnetic column (Miltenyi
Biotec) contained >95% CD4+ T cells. These cells were stained with PE-con-
jugated anti-CD44, and naive CD4+ T cells were sorted with a FACSVantage
SE cell sorter (Becton Dickinson). 13 106 purified naive CD4+ T cells were cul-
tured in 12-well plates in the presence of 3 mg/ml of anti-CD3 and 3 mg/ml of
anti-CD28, with 5 3 106 T cell-depleted splenocytes. For Th1 cell differentia-
tion, murine IL-12 (10 ng/ml) and anti-IL-4 (10 mg/ml) were added to the culture
media. For Th2 cell differentiation, murine IL-4 (1000 U/ml) was added along
with anti-IL-12 (10 mg/ml) and anti-IFN-g (10 mg/ml). After 72 hr, the cells562 Immunity 29, 551–564, October 17, 2008 ª2008 Elsevier Inc.were harvested and restimulated with immobilized anti-CD3 (3 mg/ml) and
anti-CD28 (3 mg/ml) for 6 hr in the presence of 2 mM monensin (Calbiochem)
for the last 2 hr. The cells were fixed with 4% paraformaldehyde, permeabilized
in buffer (PBS containing 0.1% BSA and 0.5% Triton X-100), and stained with
FITC-conjugated anti-IFN-g and PE-conjugated anti-IL-4. The expression of
intracellular cytokines was determined with a FACSCalibur (Becton Dickinson)
and analyzed with FlowJo software (Treestar).
Chemical Crosslinking, Immunoprecipitation, and Immunoblotting
Chemical crosslinking, immunoprecipitation, and immunoblotting of proteins
were performed as described (Maiti et al., 2005).
BRET Assay
BRET assay was performed following the method of Pfleger and Eidne (Pfleger
and Eidne, 2006). In brief, 293T cells were transfected with 1.0 mg of the donor
plasmid pIL-4Ra-LUC-N3 and 3.0 mg of an acceptor plasmid pGFP2-N2 (empty
vector), STAT6-GFP2-N2 or PTP1B-D181A-GFP2-N2, with Lipofectamine 2000
(Invitrogen). After 48 hr, cells were washed with PBS and collected in BRET2
buffer (Dulbecco’s PBS supplemented with 0.05 g/l CaCl2, 0.05 g/l MgCl2,
and 0.1 g/l glucose), washed twice, and resuspended at 2.5 3 107 cells/ml.
Cell suspensions in 96-well plates (50 ml/well) were stimulated with 20 ng/ml
of IL-4 or left untreated, followed by addition of DeepBlueC (Perkin Elmer).
Fluorescence signals were measured at every 30 s with Victor3 Wallace Multi-
channel Reader (Perkin Elmer) with Ex395nm and Em510nm. For each time point,
BRET ratio was calculated as (fluorescence510nm/luminescence) (fluorescen-
ce510nm for donor only cells/luminescence). Each point represents mean ± SE
(n = 3).
ROS-Induced Oxidation of PTP1B
PTP1B oxidation was measured as described (Persson et al., 2004), with minor
modifications. For elimination of spontaneous PTP1B oxidation during cell
lysis, buffers were extensively deoxygenated by bubbling nitrogen gas, and
cell lysis was performed in an anaerobic chamber with a continuous flow of ni-
trogen gas. After indicated treatments, cells were washed with deoxygenated
cold PBS and lysed with deoxygenated lysis buffer (20 mM Tris [pH 7.5], 1%
NP-40, 10% glycerol, 1 mM benzamidine, and 1.4 mg/ml aprotenin) in the pres-
ence or absence of 100 mM iodoacetic acid (IAA). IAA alkylates all cysteines
except the reversibly oxidized ones. Cell lysates were immunoprecipitaed
with anti-PTP1B, immobilized on protein G sepharose beads, and incubated
with 10 mM DTT to reduce the reversibly oxidized cysteine of PTP1B, which
was subsequently oxidized irreversibly to cysteine-sulfonic acid by incubation
with 100 mM PV for 1 hr at 4C. The samples were then used for immunoblot-
ting with a monoclonal antibody raised against a peptide corresponding to the
conserved PTP active site (‘‘Val-His-CysSO3H-Ser-Ala-Gly’’) in which the cat-
alytic cysteine (C215 in PTP1B) is irreversibly oxidized to cysteine-sulphonic
acid.
Statistical and Densitometric Analyses
All experiments were performed at least three times. Statistical differences
between different groups were determined with paired Student’s t test.
EMSA and immunoblot signals were quantified with ImageQuant (Molecular
Dynamics).
SUPPLEMENTAL DATA
Supplemental Data include one table and thirteen figures and can be
found with this article online at http://www.immunity.com/supplemental/
S1074-7613(08)00429-9.
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